Search

Your search keyword '"Maartense, E"' showing total 156 results
Start Over Author "Maartense, E"
156 results on '"Maartense, E"'

1. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

Author

Charehbili, A., van de Ven, S., Smit, V.T.H.B.M., Meershoek-Klein Kranenbarg, E., Hamdy, N.A.T., Putter, H., Heijns, J.B., van Warmerdam, L.J.C., Kessels, L., Dercksen, M., Pepels, M.J., Maartense, E., van Laarhoven, H.W.M., Vriens, B., Wasser, M.N., van Leeuwen-Stok, A.E., Liefers, G.J., van de Velde, C.J.H., Nortier, J.W.R., and Kroep, J.R.

Published
2014
Full Text
View/download PDF

2. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

Author

Smorenburg, C.H., de Groot, S.M., van Leeuwen-Stok, A.E., Hamaker, M.E., Wymenga, A.N., de Graaf, H., de Jongh, F.E., Braun, J.J., Los, M., Maartense, E., van Tinteren, H., Nortier, J.W.R., and Seynaeve, C.

Published
2014
Full Text
View/download PDF

3. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group

Author

Hamaker, M.E., Seynaeve, C., Wymenga, A.N.M., van Tinteren, H., Nortier, J.W.R., Maartense, E., de Graaf, H., de Jongh, F.E., Braun, J.J., Los, M., Schrama, J.G., van Leeuwen-Stok, A.E., de Groot, S.M., and Smorenburg, C.H.

Published
2014
Full Text
View/download PDF

15. Comorbidity and treatment decision-making in elderly non-Hodgkin's lymphoma patients: a survey among haematologists

Author

van der Poel, M.W.M., Mulder, W.J.M., Ossenkoppele, G.J., Maartense, E., Wijermans, P., Hoogendoorn, M., Schouten, H.C., RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Hematologie (9), Interne Geneeskunde, Hematology, and CCA - Innovative therapy

Subjects
non-Hodgkin's lymphoma, survey, Comorbidity, elderly
Abstract

Background: Elderly patients with non-Hodgkin's lymphoma (NHL) are often not treated with standard immunochemotherapy and this might have a negative impact on their survival. Little is known about the determinants that play a role in treatment decision-making of clinicians regarding elderly patients with NHL. The objective of this study was to gain more insight into these determinants.Methods: A survey was conducted amongst haematologists in the Netherlands. The survey contained questions about comorbidity, polypharmacy, social setting, nutritional status, depression, mild cognitive impairment, dementia, activities of daily living (ADL) and instrumental activities of daily living (IADL) in relation to treatment decisions in elderly NHL patients.Results: Of all comorbidities, respondents designated cognitive disorders and cardiovascular comorbidity as the most important factors when assessing whether an older patient with NHL is eligible for curative treatment. Also in decreasing degree of importance ADL, IADL and depressive disorder are frequently included in treatment decision-making. Almost half of the respondents feel that treatment of the elderly person is complicated as a result of a lack of scientific evidence.Conclusion: Haematologists are aware of coexisting problems in elderly patients and they frequently take comorbidities, cognitive disorders and functional status into consideration in treatment decision-making. Future studies are needed to determine the exact role that these factors should play in the treatment of elderly patients. Furthermore, haematologists feel that treatment of the elderly is complicated and there is a lack of scientific evidence, and therefore older adults should be better represented in clinical trials.

Published
2014

16. Abstract P2-09-08: Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)

Author

Blok, EJ, primary, Kroep, JR, additional, Meershoek-Klein Kranenbarg, EM, additional, Duym-de Carpentier, M, additional, Putter, H, additional, van den Bosch, J, additional, Maartense, E, additional, van Leeuwen-Stok, AE, additional, Liefers, G-J, additional, Nortier, JWR, additional, Rutgers, EJT, additional, and van de Velde, CJH, additional

Published
2017
Full Text
View/download PDF

17. Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

Author

Blok, EJ, primary, van de Velde, CJH, additional, Meershoek-Klein Kranenbarg, EM, additional, Putter, H, additional, van den Bosch, J, additional, Maartense, E, additional, van Leeuwen-Stok, AE, additional, Liefers, G-J, additional, Nortier, JWR, additional, Rutgers, EJT, additional, and Kroep, JR, additional

Published
2017
Full Text
View/download PDF

18. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)

Author

Van de Velde, C.J.H., primary, Blok, E., additional, Meershoek-Klein Kranenbarg, E., additional, Putter, H., additional, Van den Bosch, J., additional, Maartense, E., additional, Duijm-de Carpentier, M., additional, Van Leeuwen-Stok, E., additional, Liefers, G.J., additional, Nortier, J., additional, Rutgers, E., additional, and Kroep, J., additional

Published
2017
Full Text
View/download PDF

20. The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists' group (BOOG) side-study

Author

Dekker, T.J.A., Charehbili, A., Smit, V.T.H.B.M., Wasser, M.N.J.M., Heijns, J.B., Warmerdam, L.J. van, Kessels, L., Dercksen, W., Pepels, M., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Kranenbarg, E.M.K., Velde, C.J.H. van de, Liefers, G.J., Nortier, H.W.R., Tollenaar, R.A.E.M., Mesker, W.E., and Kroep, J.R.

Published
2013

21. Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): A Dutch breast cancer trialists group (BOOG) side-study

Author

Charehbili, A., Hamdy, N.A.T., Smit, V.T.H.B.M., Liefers, G.J., Putter, H., Kranenbarg, E.M.K., Heijns, J.B., Warmerdam, L.J. van, Kessels, L.W., Dercksen, W., Pepels, M.J., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Leeuwen-Stok, E. van, Velde, C.J.H. van de, Nortier, H.W.R., and Kroep, J.R.

Published
2013

22. NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)-A Dutch Breast Cancer Trialists' Group (BOOG) study

Author

Charehbili, A., Ven, S. van de, Liefers, G.J., Smit, V.T.H.B.M., Putter, H., Heijns, J.B., Warmerdam, L. van, Kessels, L., Dercksen, W., Pepels, M.J., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Wasser, M.N., Hamdy, N.A.T., Kranenbarg, E.M.K., Leeuwen-Stok, E. van, Velde, C.J.H. van de, Kroep, J.R., and Nortier, J.W.R.

Published
2013

24. NEO-ZOTAC: Toxicity data of a phase Ill randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)

Author

Yen, S.V. de, Liefers, G.J., Putter, H., Warmerdam, L.J. van, Kessels, L.W., Dercksen, W., Pepels, M.J., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Smit, V.T.H.B.M., Wasser, M.N.J.M., Meershoek-Klein, K.E.M., Leeuwen-Stok, E. van, Velde, C.J.H. van de, Nortier, J.W.R., and Kroep, J.R.

Published
2012
Full Text
View/download PDF

26. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

Author

Mieog, Js, Morden, Jp, Bliss, Jm, Coombes, Rc, van de Velde CJ, IES Steering Committee: Delozier, T, Veronesi, A, Vrdoljak, E, Monnier, A, Coombes, C, Nagykalnai, T, Roumen, Rm, Utracka Hutka, B, Pluzanska, A, Porpiglia, M, Genta, F, Benedetto, Chiara, Sozzani, P, Steiner, M, Rubinov, R, Leviov, M, Semiglazov, V, Fox, J, Mayordomo, Ji, Cervek, J, Sleeboom, Hp, Jassem, J, Hinton, Cp, Paulsen, Th, Guleng, Rj, Fein, L, Gutulescu, N, Florián, J, Rosso, R, Rutgers, Ej, Krzakowski, M, Pienkowski, T, Krajina, Z, Siffnerova, H, Pawlicki, M, Drosik, K, Wagnerowa, M, Brunt, M, Vukelja, S, Mitrowic, L, Cataliotti, L, Karnicka Mlodkowska, H, Bonnefoi, H, Tilch, G, Chollet, P, Patel, A, Kamby, C, Giustini, L, Acito, L, Mouridsen, H, Roche, H, De Lafontan, B, Tomczak, P, Petruzelka, L, Lortholary, A, Pacquola, Mg, Skene, A, Rici, S, Michelotti, A, Ghilezan, N, Stewart, A, Beauduin, M, Andersen, J, Vassilaros, S, Celio, L, Bajetta, E, Bastús, R, Marsland, T, Paridaens, R, Tzekova, V, Lichtenegger, W, Piersma, H, Jones, S, Holmberg, S, Verhoeven, D, Hill, A, Porcile, G, Bruno, Mf, Chernozemski, I, Coleman, R, Jadeja, J, Cohn, A, Merlano, M, Perroni, D, Di Costanzo, F, Van Bochove, A, Gerrits, Ma, Malec, V, Balil, A, Mendiola, C, Dodwell, D, Knox, R, Horgan, K, Joannides, T, Leonard, Rc, Cawthorn, Sj, Ghosh, C, Cantrell, J, Campos, D, Orti, R, Diedrich, K, Aas, H, Barnadas, A, Vila, Mm, Makris, A, Anderson, T, Chittor, S, Michel, J, Philip, P, Redmond, P, Mastboom, Wj, Nordenskjöld, B, Simmonds, P, Grieve, Rj, Tomova, A, Piot, G, Borea, G, Ucci, G, Einarsson, E, Nicholson, S, Gardiol, Ea, Kerger, J, Schlosser, J, Namer, M, Pinotti, G, Rutten, Ht, Iversen, T, Nejim, A, Dudov, A, Grundtvig, P, Lang, I, Massidda, B, Van De Velde CH, Gervasio, Mh, Tengrup, I, Tennvall, L, Goodman, S, Modgill, Vk, Vorobiof, Da, Mickiewicz, E, Chirgwin, J, Focan, C, Albin, N, Contu, Aa, Svensson, Jh, Borghede, G, Källström, Ac, Forbes, Jf, Hurtz, Hj, Tubiana Hulin, M, Viens, P, Scanni, A, Arnoldi, E, Nastasi, G, Bottini, A, Alquati, P, Muscat, V, Brincat, S, Holmen, K, Amaral, N, Moreno, I, Trask, C, Robinson, A, Mcintyre, K, Otsuka, A, Hohaus, B, Hoefig, G, Georgoulias, V, Salvagni, S, Bidin, L, Artioli, F, Engan, T, Benedikstsson, Kp, Campbell, I, Harvey, V, Zimbler, H, Mrsic Krmpotic, Z, Canon, Jl, Tchilingirov, Pv, Buser, K, Bolanca, A, Reztke, U, Rhein, U, Jouve, M, Mullins, G, Vesentini, L, Gallo, L, Merlini, L, Decensi, A, Carreca, I, Van Tienhoven, G, Börjesson, B, Hansen, J, Koza, I, Arcusa, A, Inoriza, A, Pelegri, A, Eremin, O, Modiano, Mr, Anthony, S, Donat, D, Richardet, E, Kochli, O, Zeißig, P, Gauch, G, Aabo, K, Fumoleau, P, Erdkamp, Fl, Lovén, L, Jönsson, Pe, Perren, T, Stuart, N, Galindo, E, Marek, Bj, Salmon, Jp, Dohollou, N, Thompson, R, Folco, U, Rosa, A, Tonato, M, Heijmans, Gj, Koralewski, P, Bång, H, Lescure, Ar, Carrato, A, Martin, M, Neave, F, Howell, T, Savin, M, Loesch, D, Hannois, A, Mohr, A, Laube, T, Omar, S, Bonneterre, J, Servent, V, Danese, S, Sertoli, Mr, Butzelaar, Rm, Steller, Ep, Gomez, H, Skoog, P, Alvarez, I, Aguilar, Ea, Giner, Jl, Yosef, Hm, Barrett Lee, P, Buzdar, Au, George, T, Olivaires, J, Vsianska, M, Köhler, U, Lindeløv, B, Toftdahl, Db, Nielsen, Eb, Veyret, C, Castera, D, Kerbrat, P, Vassilaros, P, Yeo, W, Boni, C, Aitini, E, Luporini, G, Herben, Mg, Espelid, H, Dahl, S, Ingvar, C, Meana, A, Pico, C, Garcia, Am, Agrawal, Rk, Gruenberg, D, Nunez de Pierro, A, Gill, G, Nogaret, Jm, Honhon, B, Wassenaar, H, Nielander, R, Warnier, P, Sessa, C, Padrik, P, Guastalla, Jp, Serin, D, Jaubert, D, Dank, M, Given, Fh, Mascia, V, De Fraia, E, Silingardi, V, Conte, Pf, Labianca, R, Tondini, C, Bagnulo, A, Gardani, G, Wils, J, Liem, G, Nuytinck, Jk, Formoe, E, Ambré, T, Alés, J, Aramburo, P, Mansi, J, Graham, J, Joffe, J, Sainsbury, J, Stone, J, Good, Rh, Cartwright, T, Werner, Id, Murray, E, Beith, J, Tigges, Fj, Bojko, P, Sandberg, E, Jensen, B, Lotz, Jp, Carney, D, Shapira, J, Neumann, A, Goldhirsch, A, Dicato, M, de Graaf, H, Maartense, E, Burghouts, J, Cassinello, J, Jones, A, Gaffney, C, Blum, R, Abdi, E, Becquart, D, Dirix, L, Janssens, J, Nmarschner, N, Blaska Jaulerry, B, Prevot, G, Mirah Lev, L, Shani, A, Baruch, Nb, Peretz, T, Gips, M, Cognetti, F, Carlini, P, Nortier, Jw, Huinink D, ten B., Roussel, Jg, Unneberg, K, Kylberg, F, Hovind, H, Nestvold, T, Fogelkvist, R, Due, J, Muller, S, Gilligan, D, Russel, S, Mcaleer, J, Yiangou, C, Foote, L, Schottstaedt, M, Holmes, Fa, Wainstein, R, Contreras, O, Martinez, J, Della Fiorentina, S, Beslija, S, Vermorken, Jb, Thirion, M, Fraikin, J, Castiglione, M, Jäger, W, Fasching, P, Fabriz, H, Neis, K, Kirschbaum, M, Labat, Jp, Dupuis, O, Bernard, J, Datchary, J, Provencal, J, Allain, P, Clerico, M, Lopez, M, Nalli, G, Aspevik, R, Fràguas, A, Curescu, S, Cuevas, Jm, Oltra, A, Bradley, C, Kapoor, R, Akbain, S, Croghan, Mk, Modiano, M, Taetle, R, Beale, P, Gobert, P, Bondue, H, Böhm, R, Møller, Ka, Brettes, Jp, Netter, G, Grogan, L, Klein, B, Botta, M, Barni, S, Van Meerwijk, I, Kåresen, R, Godes, J, Aramburo, A, Jara, C, Zanger, B, Fleagle, Jt, Greenspan, A, Marschke, R, Medgyesy, Dc, Garbo, L., CCA -Cancer Center Amsterdam, and Radiotherapy

Subjects
medicine.medical_specialty, Population, Breast Neoplasms, Disease-Free Survival, chemistry.chemical_compound, Breast cancer, Exemestane, Internal medicine, Surveys and Questionnaires, medicine, Clinical endpoint, Humans, Carpal tunnel syndrome, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Aromatase Inhibitors, Hazard ratio, Middle Aged, medicine.disease, Carpal Tunnel Syndrome, Surgery, Musculoskeletal Abnormalities, Androstadienes, Postmenopause, Tamoxifen, Treatment Outcome, Oncology, chemistry, Hormonal therapy, Female, business, medicine.drug
Abstract

BACKGROUND: Aromatase inhibitors are more effective than is tamoxifen in prevention of breast-cancer recurrence, but at the expense of increased musculoskeletal side-effects, such as carpal tunnel syndrome. The aim of this study was to assess risk factors and the prognostic value of musculoskeletal symptoms during treatment with the steroidal aromatase inhibitor exemestane or with tamoxifen after 2-3 years of tamoxifen. METHODS: In the Intergroup Exemestane Study, postmenopausal women treated for early invasive breast cancer who remained disease free and on treatment after 2-3 years of tamoxifen were randomised to switch to exemestane or to continue tamoxifen for the remainder of the 5-year period of endocrine treatment. The primary endpoint for this retrospective analysis was occurrence of carpal tunnel syndrome and any musculoskeletal events, analysed in the safety population, which consisted of all patients who had received any trial treatment. As well as case-report forms, questionnaires were distributed retrospectively to gain more details of cases of carpal tunnel syndrome. The relation between musculoskeletal symptoms reported by 6 months from randomisation and survival from 9 months onwards was assessed by Cox proportional hazards models. The trial is registered, number ISRCTN11883920. It has completed accrual and follow-up is continuing for enrolled participants. FINDINGS: After a median follow-up of 91·0 months (IQR 83·0-99·2), carpal tunnel syndrome had been reported for 66 (2·8%) of 2319 patients in the exemestane group compared with 13 (0·6%) of 2338 in the tamoxifen group (odds ratio [OR] 5·23, 99% CI 2·39-11·49; p

Published
2012

28. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational

Author

Nes, J.G.H. van, Seynaeve, C., Maartense, E., Roumen, R.M.H., Jong, R.S. de, Beex, L.V.A.M., Kranenbarg, W.M.M.K., Putter, H., Nortier, J.W.R., Velde, C.J.H. van de, Cooperating Investigators Dutch TE, Medical Oncology, and Erasmus MC other

Subjects
medicine.medical_specialty, Neoplasms, Hormone-Dependent, medicine.medical_treatment, Sentinel lymph node, Breast Neoplasms, Quality of Care [ONCOL 4], chemistry.chemical_compound, Breast cancer, Exemestane, SDG 3 - Good Health and Well-being, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Practice Patterns, Physicians', Survival rate, Aged, Retrospective Studies, Gynecology, business.industry, International Agencies, breast cancer endocrine therapy guideline patterns of care aromatase inhibitors decision-making therapy women survival netherlands mastectomy carcinoma recommendations management, Cancer Care Facilities, Hematology, Middle Aged, medicine.disease, Combined Modality Therapy, Clinical trial, Androstadienes, Postmenopause, Survival Rate, Tamoxifen, Treatment Outcome, Oncology, chemistry, Receptors, Estrogen, Chemotherapy, Adjuvant, Practice Guidelines as Topic, Female, business, Receptors, Progesterone, Mastectomy, medicine.drug
Abstract

Item does not contain fulltext BACKGROUND: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial investigates the efficacy and safety of adjuvant exemestane alone and in sequence after tamoxifen in postmenopausal women with hormone-sensitive early breast cancer. As there was a nationwide participation in The Netherlands, we studied the variations in patterns of care in the Comprehensive Cancer Centre Regions (CCCRs) and compliance with national guidelines. METHODS: Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected. RESULTS: From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < or =2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001). DISCUSSION: In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement. 01 mei 2010

Published
2010

31. Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators

Author

André, T., primary, De Gramont, A., additional, Chibaudel, B., additional, Raballand, A., additional, Duval, A., additional, Hickish, T., additional, Tabernero, J., additional, van Laethem, J., additional, Banzi, M., additional, Maartense, E., additional, Shani, A., additional, Carlsson, G., additional, Scheithauer, W., additional, Papamichael, D., additional, Moehler, M., additional, Landolfi, S., additional, Demetter, P., additional, Dumont, S., additional, and Fléjou, J., additional

Published
2014
Full Text
View/download PDF

32. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

Author

Nes, J.G. van, Seynaeve, C., Maartense, E., Roumen, R.M., Jong, R.S. de, Beex, L.V.A.M., Meershoek-Klein Kranenbarg, W.M., Putter, H., Nortier, J.W., Velde, C.J. van de, Nes, J.G. van, Seynaeve, C., Maartense, E., Roumen, R.M., Jong, R.S. de, Beex, L.V.A.M., Meershoek-Klein Kranenbarg, W.M., Putter, H., Nortier, J.W., and Velde, C.J. van de

Abstract

1 mei 2010, Item does not contain fulltext, BACKGROUND: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial investigates the efficacy and safety of adjuvant exemestane alone and in sequence after tamoxifen in postmenopausal women with hormone-sensitive early breast cancer. As there was a nationwide participation in The Netherlands, we studied the variations in patterns of care in the Comprehensive Cancer Centre Regions (CCCRs) and compliance with national guidelines. METHODS: Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected. RESULTS: From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < or =2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001). DISCUSSION: In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement.

Published
2010

33. Abstract P1-08-19: Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): A Dutch breast cancer trialists group (BOOG) side-study

Author

Charehbili, A, primary, Hamdy, NAT, additional, Smit, VTHBM, additional, Liefers, G-J, additional, Putter, H, additional, Meershoek-Klein Kranenbarg, E, additional, Heijns, JB, additional, van Warmerdam, LJ, additional, Kessels, LW, additional, Dercksen, W, additional, Pepels, MJ, additional, Maartense, E, additional, van Laarhoven, HWM, additional, Vriens, B, additional, van Leeuwen-Stok, E, additional, van de Velde, CJH, additional, Nortier, HWR, additional, and Kroep, JR, additional

Published
2013
Full Text
View/download PDF

34. Abstract P1-06-04: The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists’ group (BOOG) side-study

Author

Dekker, TJA, primary, Charehbili, A, additional, Smit, VTHBM, additional, Wasser, MNJM, additional, Heijns, JB, additional, van Warmerdam, LJ, additional, Kessels, L, additional, Dercksen, W, additional, Pepels, M, additional, Maartense, E, additional, van Laarhoven, HWM, additional, Vriens, B, additional, Meershoek-Klein Kranenbarg, E, additional, van de Velde, CJH, additional, Liefers, G-J, additional, Nortier, HWR, additional, Tollenaar, RAEM, additional, Mesker, WE, additional, and Kroep, JR, additional

Published
2013
Full Text
View/download PDF

35. Abstract PD07-06: NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)

Author

van de Ven, S, primary, Liefers, G-j, additional, Putter, H, additional, van Warmerdam, LJ, additional, Kessels, LW, additional, Dercksen, W, additional, Pepels, MJ, additional, Maartense, E, additional, van Laarhoven, HWM, additional, Vriens, B, additional, Smit, VTHBM, additional, Wasser, MNJM, additional, Meershoek-Klein, Kranenbarg EM, additional, van Leeuwen-Stok, E, additional, van de Velde, CJH, additional, Nortier, JWR, additional, and Kroep, JR, additional

Published
2012
Full Text
View/download PDF

36. Abstract P1-12-05: First-line chemotherapy with pegylated liposomal doxorubicin versus capecitabine in elderly patients with metastatic breast cancer: results of the phase III OMEGA study of the Dutch Breast Cancer Trialists' Group (BOOG)

Author

Smorenburg, CH, primary, Seynaeve, C, additional, Wymenga, MANM, additional, Maartense, E, additional, de Graaf, H, additional, de Jongh, FE, additional, Braun, HJ, additional, Los, M, additional, Schrama, JG, additional, Portielje, JEA, additional, Hamaker, M, additional, van Tinteren, H, additional, de Groot, SM, additional, van Leeuwen-Stok, EAE, additional, and Nortier, HWR, additional

Published
2012
Full Text
View/download PDF

37. 249 Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists’ Group (BOOG)

Author

Seynaeve, C., primary, van Tinteren, H., additional, Wymenga, A.N.M., additional, Nortier, J.W.R., additional, Maartense, E., additional, de Jongh, F.E., additional, de Graaf, H., additional, de Groot, S.M., additional, and Braun, J.J., additional

Published
2012
Full Text
View/download PDF

39. Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer.

Author

Dezentje, V. O., primary, den Hartigh, J., additional, Guchelaar, H., additional, Hessing, T., additional, van der Straaten, T., additional, Vletter - Bogaartz, J. M., additional, Vree, R., additional, Maartense, E., additional, Smorenburg, C. H., additional, Putter, H., additional, Dieudonné, A., additional, Neven, P., additional, Nortier, J. W. R., additional, and Gelderblom, H., additional

Published
2011
Full Text
View/download PDF

40. Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment

Author

von Minckwitz, G, primary, Schwedler, K, additional, Schmidt, M, additional, Barinoff, J, additional, Mundhenke, C, additional, Cufer, T, additional, Maartense, E, additional, de Jongh, F, additional, Baumann, K, additional, Bischoff, J, additional, Harbeck, N, additional, Lück, H-J, additional, Maass, N, additional, Zielinski, C, additional, Andersson, M, additional, Stein, R, additional, Nekljudova, V, additional, and Loibl, S., additional

Published
2010
Full Text
View/download PDF

42. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study.

Author

Poel, M., Mulder, W., Ossenkoppele, G., Maartense, E., Hoogendoorn, M., Wijermans, P., and Schouten, H.

Subjects
DIFFUSE large B-cell lymphomas, OLDER patients, DECISION making, HEMATOLOGISTS, CANCER chemotherapy, SOCIAL support, THERAPEUTICS
Abstract

Elderly patients with diffuse large B-cell lymphoma (DLBCL) are frequently not treated with standard immunochemotherapy, and this influences survival negatively. The purpose of this study was to gain more insight into treatment decision-making by hematologists. Case vignettes concerning patients with DLBCL were presented to hematologists in the Netherlands. Patient characteristics (age, comorbidity) differed per case. Respondents were asked in each case if they would treat the patient with curative intent by means of full-dose chemotherapy or chemotherapy with dose reduction or if they would not treat the patient with curative intent. The vast majority of respondents would treat an elderly patient diagnosed with DLBCL without a relevant medical history with full-dose chemotherapy irrespective of age. In the presence of comorbidity, lack of social support, cognitive disorders, and untreated depression dose reductions in advance are frequently applied or patients are not treated with curative intent. This is most pronounced for patients aged older than 80 years. Respondents working in a university hospital more frequently refrain form full-dose chemotherapy with curative intent compared to respondents working in tertiary medical teaching hospitals or general hospitals. Patients without a relevant medical history are generally treated with curative intent irrespective of age. Cognitive disorders, comorbidity, and depression reduce the change of being treated with curative intent. This is most prominent in the eldest patient category. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results